Nitrosamine Risk Management: Your Questions Answered

Managing nitrosamine impurities and nitrosamine drug substance-related impurities requires early evaluation during formulation development to avoid costly delays and complex reformulation. Manufacturers must identify vulnerable amines, trace nitrite sources in excipients using sensitive techniques like pre-column derivatization, and address analytical challenges involving extremely low concentrations and complex separation from active pharmaceutical ingredients. When commercial reference standards are absent, custom synthesis is necessary rather than relying on the active pharmaceutical ingredient as a substitute. Comprehensive risk assessments should be continuously updated whenever manufacturing processes, suppliers, or packaging materials change.

To explore effective mitigation strategies, analytical testing methods, and expert insights on maintaining compliance, read the article.